CONFIDENTIAL DELIVERING INNOVATION. WHERE IT’S NEEDED. Implementing a New Clinical Systems Strategy David Templeton – Clinical Systems ManagerWho Is Intersect ENT A medical device company dedicated to advance the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, and solutions for physicians to overcome clinical challenges and improve the quality of life for patients. 2Who Is Intersect ENT 3 event 2 2009-2010 Pivotal study 105 patients 2006 Development begins PROPEL (device) 2011 FDA Approval 2014-2016 Study 2: 300 patients 2008 Development begins Sinuva (drug) 2017 FDA Approval 2013-2014 Study 1: 100 patients Founded in 2003 | 325+ employees today | Approx. 2 studies per year 2011-2012 Pilot studies 2014-2016 PROPEL Mini & Contour 16

Join for free to read